Boon of the BPal Regime: Bane for Multi Drug Resistant Tuberculosis in India
DOI:
https://doi.org/10.47363/JPRR/2024(6)184Keywords:
Tuberculosis , Drug Resistant, Delamanid , PretomanidAbstract
A novel regime for treatment of MDR TB has been launched consisting of BDQ, PRT and LNZ. Immense potential lies in its short term (6 months), efficacious drugs and lesser adverse events. A very good cure rate of around 90% have been achieved in Clinical trials including one from India. A contingent as well as circumspect roll out of the regime in all parts of India may be momentous for MDR TB control and TB elimination.
Downloads
Published
2024-11-01
Issue
Section
Articles